Lab test of treatments for EGFR-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study uses leftover tissue or fluid from your lung cancer to test how it responds to different drugs in the lab. The goal is to understand which treatments might work best for tumors with EGFR mutations, which could help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have been diagnosed with non-small cell lung cancer (the most common type of lung cancer).
- Your cancer cells have a specific change called an EGFR mutation (a type of gene change that can be targeted by certain drugs).
- You have left-over tissue or fluid samples from past medical procedures (like a biopsy or surgery) that can be used for this research.
- You must sign a written consent form agreeing to let your samples be studied.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study looks at real-world information from people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to understand how patients are treated and what outcomes they have, which may help improve future care.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.